Abstract
Introduction
The law must move. It cannot be an objective, or a thing achieved. It is rather a journey, or a thing continually contemplated -a work in progress. It must constantly be in motion if it is to address the past, speak to the present, and remain relevant into the future. Indeed, it has been noted time and again, from the landmark 'persons case' in Canada, 1 to more contemporary claims in the technology context, 2 that the law must adapt, respond and thereby evolve, and it must not be left to stultify. The law simply cannot afford to stand still. And indeed the law does move and grow, albeit often in a reactive sort of way.
By way of example, Korea has experienced a brief period of high turnover of ideas and reform proposals in the medical law field, which is undergoing a significant transformation in both the clinical and research settings as a result of technological innovations.
3 However, just as it seemed a new research regime had been agreed through the combination of the Bioethics and Biosafety Amendment Bill 4 and the Reproductive Cells Utilisation and Supervision Bill, 5 politics intervened. These proposals, which had been identified by the Ministry of Health, Welfare and Family Affairs (MOHWFA) as legislative priorities, were abandoned when the 17th National Assembly was ended; and the 'wholesale amendment' of a legal regime that had failed so dramatically to curb the excesses and dishonesty of the immediately preceding 'Hwang era' was abandoned with them.
However, as claimed above, the law cannot and does not stand still, and everyone knew that the Korean law governing medical research could not afford to remain unchanged. In place of the abandoned Bills, a new Bioethics Amendment Bill Draft 17-8353 alters or clarifies the boundaries of legal conduct with respect to several of these issues, and the remainder of this short article considers the old and new positions with respect to (1) core definitions and principles, (2) permissible research and conduct, (3) participant protections and (4) ethical oversight and enforcement.
Core Definitions and Principles
Although the BBA 2005 directs researchers to endeavour to safeguard human dignity and to carry out their work in accordance with the principles of bioethics and biosafety, 10 it contains no explicit reference to any mid-level guiding principles, nor to any relevant international instruments. It does state that care must be exercised when storing, handling and disposing of remaining embryos, and that research must be halted or appropriate measures taken when research poses a significant or potential threat to bioethics or biosafety.
11 Nevertheless, there is no elucidation of the standards entailed by which bioethics or demanded for biosafety. Draft 17-8353 adds almost nothing to our understanding of the core principles or standards of bioethics in Korea, its only new provision being a reference to anonymisation of genetic information in DNA banks.
12 Although this constitutes an important privacy protection, it was envisioned in some quarters as having the effect of vitalising the DNA bank.
Permissible Research and Conduct
There are three primary areas of research and conduct that are addressed in the BBA 2005, namely embryo and reproductive research, stem cell research, and DNA banking.
With respect to embryos, the BBA 2005 states that no embryo shall be produced other than for the purpose of pregnancy (with the consequence that no artificial insemination shall be undertaken for research purposes).
13 However, embryos can be stored for up to 5 years (with the consent of the originators), after which they must be destroyed, unless they are to be used for research, in which case they must be preprimitive streak and the research must be aimed at developing contraception and infertility treatments, curing rare or incurable diseases as decreed by the President, or otherwise be approved by the President after review by the NBC.
14 The BBA 2005 clearly prohibits reproductive cloning and stipulates that no one shall conduct Somatic Cell Nuclear Transfer (SCNT) other than for research aimed at curing rare or currently incurable diseases, as decided by the President after review by the NBC.
15
Although the BBA 2005 prohibits the implantation of an animal's somatic cell nucleus into a human oocyte whose nucleus has been removed, 16 it does not prohibit the implantation of a human nucleus into an animal oocyte. Draft 17-8353 rectifies this lacunae, amending s 12 to now clearly prohibit nuclear transfer between humans and animals.
17 Additionally, Draft 17-8353 redefines SCNT, limiting it to the transfer of a human somatic cell nucleus to a human oocyte from which the nucleus has been removed. 18 With respect to stem cells more specifically, both the production and importation of stem cell lines are permitted in Korea, and some administrative standards have been erected around these processes. produce or import stem cell lines must register with the Minister of Health, must obtain IRB approval if those stem cell lines are to be offered for research, must offer them free of any charge beyond the costs associated with their storage and must apprise the Minister of the present status of the stem cell lines (i.e. inform the Minister which lines are on offer at any given time).
19 With respect to the research itself, Draft 17-8353 stipulates that stem cell research must be directed at diagnosis, prevention or treatment of diseases, furthering understanding of the characterisation and specialisation of stem cells, or some other purpose which is deemed acceptable by Executive Order. 20 This latter provision in particular clarifies the purpose for which stem cell research can be undertaken, adopting broad and inclusive purposes. Finally, any research employing stem cells must undergo prior IRB consideration, report the outcome of that deliberation to the Minister of Health, submit a plan form utilising the stem cells to the provider of the stem cells, and must comply with the chief of the research institution, who is tasked with ensuring that research conforms to the research plans submitted. 21 Finally, as noted above, the BBA 2005 addresses the creation of DNA banks and Draft 17-8353 states that both local and national support will be made available for the management of these banks, 22 though little is said about what form this support might take. Additionally, it states that genetic information held in banks must be anonymised, and the custodian of the bank must ensure the security and privacy of information. Further details relating to management, custody and custodial duties are created by Executive Order of the MOHWFA. 
Participant Protections
Protections for those participating in research are contained in provisions which address payment, consent and anonymisation of information.
Section 13 of the BBA 2005 states that no one shall provide sperm or oocytes for the purpose of financial reward, 24 presumably trying to avoid coercive situations engendered by poverty. Draft 17-8353 adds nothing to this general protective provision Section 15 of the BBA 2005 states that institutions which collect sperm or oocytes shall obtain written consent from donors, patients and spouses. Draft 17-8353 makes a number of amendments to this section with respect to egg donation procedures. First, it stipulates that the medical institution which produces the embryo must first perform a medical examination of the egg donor, and it cannot extract eggs from a woman whose health falls within certain criteria set by the MOHWFA. 25 Second, the frequency of egg extractions that any single woman can undergo is to be set by Executive Order. 26 Finally, the actual expenses associated with the egg donation (e.g. compensation for the time relating to the operation and recovery, as well as transportation costs) are compensable to the egg donor.
27 Although these are useful additions, they go nowhere near as far as the provisions of the now abrogated Reproductive Cells Utilisation and Supervision Bill, which explicitly stated that cell donors (and his/her spouse) must be sufficiently informed about the potential sideeffects and consequences of extraction and/or donation, and that egg donors must be over 20, independent, and both physically and psychologically healthy.
28
With respect to protection of patient privacy, as noted above, Draft 17-8353 makes an addition to s 35 of the BBA 2005, stipulating that, in the DNA banking context, all collected samples and genetic information must be anonymised. Again, however, it does not specify how the anonymisation will be achieved, what security measure will be expected, whether the information could, in future, be de-anonymised, and what the consequences of a security failure in this respect might be.
Ethical Oversight and Enforcement
The BBA 2005 calls for the establishment of a National Bioethics Committee (NBC), which is to review matters implicating bioethics and biosafety, including policies, research projects on remaining embryos or involving SCNT, DNA test prohibitions, gene therapy target diseases, and other issues of social or moral significance implicated by life sciences research. 29 Formed some three months after the BBA 2005 came into force, 30 it has never been clear whether the NBC is intended to be a policy advisory committee or a research oversight committee, and the ambiguity is not rectified by Draft 17-8353.
Section 9 of the BBA 2005 calls for the establishment of IRBs. IRBs are to review all matters relating to (amongst other things) research undertaken by their host institute, including ethical and scientific validity, consent and safety measures. They must conduct a review where there is a serious threat or potential threat "to bioethics and biosafety" as a result of research. Of course, in practice, the IRBs proved utterly ineffective at performing their functions.
31
Draft 17-8353 recognises this and therefore includes some provisions directed at broadening the scope of IRB protection and enhancing the effectiveness of IRBs. For example, it expands the list of institutions that must seek IRB approval before they can act, adding embryo production institutions, somatic cell embryo clone research 
Conclusion
Readers will recall our previous conclusion that reform efforts in the Korean medical research setting (e.g. Bill 7702 and the Reproductive Cells Utilisation and Supervision Bill) represented some improvement over the old regime, but evinced a certain "inertia" insofar as they clung to the desire to promote biotechnology and not unduly hinder biotech development. 38 In short, the balance achieved between biosafety promotion and reproductive health, on the one hand, and biotech promotion, on the other, remained skewed in the direction of the latter. The amendments that have now finally been adopted in Draft 17-8353 represent an equally modest renovation of the regime. Obviously, the provisions directed at greater systematisation and improvement of IRBs, and those directed at stiffening penalties for breaches, as well as expanding the failures against which they can be levelled, are an improvement. However, there is little to encourage faith that a new research governance era has dawned in Korea. Much will continue to depend on the actions of the IRBs and their host institutions and on the MOHWFA and the content and detail of the Minister of Health's Executive Orders. Of course, all of these actors failed spectacularly in their functions during the Hwang era -time and the generation of empirical evidence concerning oversight decisions will ultimately tell the tale.
